Vous avez cherché: sammenligningsstudie (Danois - Anglais)

randomiseret, sammenligningsstudie
randomised comparative study

paclitaxels proteinbinding efter administration af abraxane blev vurderet ved ultrafiltrering i et intraindividuelt sammenligningsstudie.
the protein binding of paclitaxel following abraxane was evaluated by ultrafiltration in a within-patient comparison study.

et sammenligningsstudie mellem den frysetørrede formulering og den opløste formulering viste bioækvivalens mellem de to formuleringer.
11 a comparative study between the freeze-dried and the liquid formulation showed bioequivalence between the two formulations.

hyppighederne er baseret på observationer fra det afgørende kliniske sammenligningsstudie af virkningen af thalidomid i kombination med melphalan og prednison hos patienter med tidligere ubehandlet myelomatose.
frequencies given are based on the observations during a pivotal comparative clinical study investigating the effect of thalidomide in combination with melphalan and prednisone in previously untreated multiple myeloma patients.

data fra 106 patienter, der indgik i to enkeltarmede, ublindede studier og fra 454 patienter, der blev behandlet i et randomiseret fase iii sammenligningsstudie understøtter brugen af abraxane ved metastaserende brystkræft.
data from 106 patients accrued in two single-arm open-label studies and from 454 patients treated in a randomised phase iii comparative study are available to support the use of abraxane in metastatic breast cancer.

hovedanalysen af det afgørende sammenligningsstudie hos 586 patienter med beta- thalassæmi og transfusional jernophobning viste ikke non- inferiority af exjade sammenlignet med deferoxamin i analysen af den totale patientpopulation.
the principal analysis of the pivotal comparative study in 586 patients suffering from beta- thalassaemia and transfusional iron overload did not demonstrate non-inferiority of exjade to deferoxamine in the analysis of the total patient population.

hovedanalysen af det afgørende sammenligningsstudie hos 586 patienter med beta-thalassæmi og transfusionsbetinget jernophobning viste ikke non-inferiority af deferasirox dispergible tabletter sammenlignet med deferoxamin i analysen af den totale patientpopulation.
the principal analysis of the pivotal comparative study in 586 patients suffering from beta-thalassaemia and transfusional iron overload did not demonstrate non-inferiority of deferasirox dispersible tablets to deferoxamine in the analysis of the total patient population.

i et igangværende langtids- sammenligningsstudie, var rosiglitazon, i kombinationsbehandling med metformin eller sulfonylurinstof, ikke- inferiør over for kombinationen af sulfonylurinstof plus metformin til sænkning af hbalc efter 18 måneder.
at 18 months, in an ongoing long term comparator study, rosiglitazone in dual oral therapy with metformin or a sulphonylurea was non-inferior to the combination of sulphonylurea plus metformin for lowering hba1c.

ved 18 måneder, i et igangværende langtids- sammenligningsstudie, var rosiglitazon, i kombinationsbehandling med metformin eller sulfonylurinstof, ikke- inferiør over for kombinationen af sulfonylurinstof plus metformin til sænkning af hbalc.
at 18 months, in an ongoing long term comparator study, rosiglitazone in dual oral therapy with metformin or a sulphonylurea was non-inferior to the combination of sulphonylurea plus metformin for lowering hba1c.